文献速递泌尿生殖与妇科肿瘤放疗

合并症对T3-4前列腺癌外照射放疗联合延长雄激素剥夺治疗获益的影响

The impact of comorbidities on the benefits of prolonged androgen ablation in patients with T3-4 prostate cancer treated with external beam radiation therapy.
PubMed 文献 · Radiother Oncol · 2017-07-04

该研究基于BC癌症机构两阶段队列(1993-1995年早期N=725;1999-2001年晚期N=584),评估cT3-4前列腺癌患者接受延长ADT(>18个月)联合EBRT的生存获益是否随基线总生存估计(E10)变化。结果显示晚期队列总生存更高,但获益随E10分组而异:低E10组无显著差异(43% vs 49%,p=0.54),中E10组(55% vs 64%,p=0.02)和高E10组(66% vs 77%,p=0.01)有显著获益。结论提示延长ADT联合EBRT的绝对获益在中、高E10患者中最大。

要点

  • 延长ADT联合EBRT的生存获益随基线E10分组变化,中、高E10组获益显著。
  • 低E10组(<60%)两时代总生存无统计学差异(43% vs 49%,p=0.54)。
  • 中E10组(60-90%)总生存55% vs 64%(p=0.02),高E10组(>90%)66% vs 77%(p=0.01)。

核心结论

  • 延长ADT联合EBRT的政策所带来生存获益随其他原因死亡基线风险而变化,绝对获益在中或高E10患者中最大。

研究设计与样本

  • 回顾性队列研究,选取BC癌症机构1993-1995年(早期,N=725)和1999-2001年(晚期,N=584)两个cT3-T4前列腺癌EBRT队列。
  • 从病历中提取ADT持续时间及基线预后因素(年龄、临床分期、分级、初诊PSA、Charlson合并症指数CCI)。
  • 使用年龄调整CCI计算10年生存估计(E10),将患者分为低(<60%)、中(60-90%)、高(>90%)三组,按时代用log rank检验比较实际总生存。

主要发现

  • 共318例低E10、544例中E10、447例高E10患者,中位随访11.1年。
  • E10各组间Gleason分级和T分期无统计学差异;较低E10组中位年龄和基线CCI更高(p<0.0001)。
  • 晚期队列总生存更高,但随E10分组变化:低E10组43% vs 49%(p=0.54),中E10组55% vs 64%(p=0.02),高E10组66% vs 77%(p=0.01)。

关键数值与推荐

  • 延长ADT定义为>18个月,联合EBRT用于局部晚期前列腺癌。
  • E10分组阈值:低<60%、中60-90%、高>90%。
  • 中E10组总生存55% vs 64%(p=0.02),高E10组66% vs 77%(p=0.01),低E10组43% vs 49%(p=0.54)。

临床怎么用

  • 对于cT3-4前列腺癌接受EBRT的患者,可根据年龄调整CCI估算的E10分层评估延长ADT的绝对获益。
  • 中、高E10患者从延长ADT联合EBRT中绝对获益最大,低E10患者获益不显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine whether the survival benefit associated with prolonged androgen deprivation therapy (ADT) and radiotherapy (EBRT) varies with baseline estimates of overall survival in cT3-4 prostate cancer patients (PCa). METHODS AND MATERIALS: In 1997, the BC Cancer Agency adopted as standard a policy of prolonged ADT (>18months) with EBRT for locally advanced PCa. Two cohorts of cT3-T4 PCa treated with EBRT were selected: 1993-1995 (early: N=725) and 1999-2001 (late: N=584). Duration of ADT and baseline prognostic factors (age, clinical stage, grade, presenting PSA, and Charlson index (CCI)) were abstracted from charts. Estimates of 10-year (E10) survival using an age-adjusted CCI were calculated and patients were grouped into low (<60%), medium (60-90%) and high (>90%) E10. In each E10 group, actual overall survivals were compared by era using log rank test. RESULTS: There were 318 low, 544 medium, and 447 high E10 patients with median follow-up of 11.1years. Gleason grade and T stage were not statistically different between E10 groups. As expected, median age and baseline CCI were higher in lower E10 groups (p<0.0001). Overall survival was higher in the late era, but varied with E10 group: low (43% vs. 49%, p=0.54), medium (55% vs. 64%, p=0.02) and high (66% vs. 77%, p=0.01). CONCLUSION: The policy of prolonged ADT with EBRT provides a survival benefit that varies with baseline risk of death from other causes. Absolute benefit from ADT is largest in those with medium or high E10.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Tran E, Paquette M, Jay J, et al. The impact of comorbidities on the benefits of prolonged androgen ablation in patients with T3-4 prostate cancer treated with external beam radiation therapy. Radiother Oncol. 2017. PMID: 28687398. doi:10.1016/j.radonc.2017.04.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。